139 related articles for article (PubMed ID: 6574995)
1. Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4'-epi-doxorubicin.
Villani F; Comazzi R; Lacaita G; Genitoni V; Guindani A; Martini A
Int J Clin Pharmacol Ther Toxicol; 1983 Apr; 21(4):203-8. PubMed ID: 6574995
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evaluation of myocardial toxicity of 4'-deoxydoxorubicin: experimental and clinical results.
Villani F; Comazzi R; Genitoni V; Lacaita G; Guindani A; Crippa F; Monti E; Piccinini F; Rozza A; Lanza E
Drugs Exp Clin Res; 1985; 11(3):223-31. PubMed ID: 3836127
[TBL] [Abstract][Full Text] [Related]
4. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?
Köseoğlu V; Berberoğlu S; Karademir S; Kismet E; Yurttutan N; Demirkaya E; Sungur M; Alehan D
Turk J Pediatr; 2005; 47(1):17-22. PubMed ID: 15884624
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
Jones WG; Mattsson W
Cancer Treat Rep; 1984 Apr; 68(4):675-7. PubMed ID: 6585271
[TBL] [Abstract][Full Text] [Related]
8. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
9. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.
Bertazzoli C; Bellini O; Magrini U; Tosana MG
Cancer Treat Rep; 1979; 63(11-12):1877-83. PubMed ID: 526920
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
Torti FM; Bristow MM; Lum BL; Carter SK; Howes AE; Aston DA; Brown BW; Hannigan JF; Meyers FJ; Mitchell EP
Cancer Res; 1986 Jul; 46(7):3722-7. PubMed ID: 3458531
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
Hirano S; Wakazono K; Agata N; Iguchi H; Tone H
Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387
[TBL] [Abstract][Full Text] [Related]
12. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.
Bennink RJ; van den Hoff MJ; van Hemert FJ; de Bruin KM; Spijkerboer AL; Vanderheyden JL; Steinmetz N; van Eck-Smit BL
J Nucl Med; 2004 May; 45(5):842-8. PubMed ID: 15136635
[TBL] [Abstract][Full Text] [Related]
13. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
14. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study.
Koutinos G; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
Anticancer Res; 2002; 22(2A):815-20. PubMed ID: 12014656
[TBL] [Abstract][Full Text] [Related]
15. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma.
Torti FM; Porzig KJ; Gandara DR; Volberding P; Mitchell E; Meyers FJ; Kohler M; Gribble M
Cancer Treat Rep; 1984 Dec; 68(12):1509-10. PubMed ID: 6595059
[No Abstract] [Full Text] [Related]
17. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma.
Ajani JA; Kanojia MD; Bodey GP
Cancer Treat Rep; 1984 Dec; 68(12):1507-8. PubMed ID: 6595058
[No Abstract] [Full Text] [Related]
18. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study of the cardiotoxicity of the anthracycline antibiotics, carminomycin and adriamycin, in white mice].
Gol'dberg LE; Shepelevtseva NG; Belova IP; Vertogradova TP
Antibiotiki; 1976 Dec; 21(12):1106-13. PubMed ID: 1020945
[TBL] [Abstract][Full Text] [Related]
20. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
